Medicare drug coverage

Linzess: 2027 Medicare Part D coverage

5,495 of 5,495 Part D plans (100%) list Linzess on their 2027 formulary, the same share as 2026. 98% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Linzess is number 25 by total Medicare Part D spending in 2024 ($2 billion). Plans that list it most often put it on tier 3. Counts use 4 RxNorm products for this name.

Linzess Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,517 (100%)5,495 (100%)no change
Prior authorization (of plans that list it)16 (0%)16 (0%)no change
Step therapy (of plans that list it)0 (0%)32 (1%)+1 point
Quantity limit (of plans that list it)5,302 (96%)5,382 (98%)+2 points
Any of the three (of plans that list it)5,318 (96%)5,398 (98%)+2 points
Not listed or restricted (of all plans)5,319 (96%)5,398 (98%)+2 points

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Linzess formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1163 (3%)123 (2%)
Tier 213 (0%)313 (6%)
Tier 34,872 (88%)5,059 (92%)
Tier 4469 (9%)0 (0%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 95 of them (2%) added prior authorization, step therapy, or a quantity limit for Linzess, and 0 stopped listing it.

Linzess: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 20270 (0%)
Listed it in 2027, not in 20260 (0%)
Moved it to a higher tier44 (1%)
Added prior authorization1 (0%)
Added step therapy21 (0%)
Added a quantity limit73 (2%)
Added at least one of the three95 (2%)
Removed at least one of the three1 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Linzess off the formulary or list it with prior authorization, step therapy, or a quantity limit. Pennsylvania ranks first at 100%, with 9% of its plans using prior authorization or step therapy; Maryland ranks last at 80%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Linzess, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Pennsylvania324100%9%no change
2Nevada100100%3%+4 points
3Ohio173100%2%no change
4Alaska9100%0%no change
5Alabama115100%0%no change
6Arkansas86100%0%no change
7Arizona148100%0%+4 points
8Connecticut54100%0%+4 points
9Delaware43100%0%no change
10Florida549100%0%no change
11Iowa64100%0%no change
12Idaho45100%0%no change
13Illinois133100%0%no change
14Indiana140100%0%no change
15Kansas84100%0%no change
16Kentucky123100%0%no change
17Louisiana126100%0%no change
18Massachusetts92100%0%+23 points
19Maine52100%0%no change
20Michigan183100%0%no change
21Minnesota63100%0%no change
22Missouri171100%0%no change
23Mississippi105100%0%no change
24Montana27100%0%no change
25North Carolina177100%0%no change
26North Dakota26100%0%no change
27Nebraska51100%0%no change
28New Hampshire25100%0%no change
29New Jersey74100%0%no change
30New Mexico68100%0%+5 points
31New York215100%0%no change
32Oklahoma81100%0%no change
33Rhode Island29100%0%no change
34South Carolina91100%0%no change
35South Dakota30100%0%no change
36Tennessee157100%0%no change
37Texas412100%0%+1 point
38Utah53100%0%no change
39Vermont14100%0%no change
40West Virginia70100%0%no change
41Wyoming13100%0%no change
42Wisconsin9799%0%no change
43Washington11497%11%+1 point
44Virginia14596%1%no change
45Oregon9296%0%no change
46Georgia15195%0%no change
47Colorado10690%0%+3 points
48Hawaii5088%0%+1 point
49California39788%0%+13 points
50District of Columbia2186%0%-2 points
51Maryland4980%0%-5 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Linzess off or restrict it.

Linzess coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.884100%100%100%no change0
UnitedHealth Group, Inc.850100%100%100%no change0
Devoted Health, Inc.728100%100%100%no change0
CVS Health Corporation633100%100%100%no change0
Elevance Health, Inc.294100%100%100%no change0
Centene Corporation268100%100%100%no change0
Health Care Service Corporation231100%100%100%no change0
Kaiser Foundation Health Plan, Inc.112100%14%14%no change1
Highmark Health98100%100%100%no change0
SCAN Group85100%100%100%+100 points54
Alignment Healthcare USA, LLC77100%100%100%no change0
Guidewell Mutual Holding Corporation55100%100%100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.43100%100%100%no change0
Molina Healthcare, Inc.43100%100%100%no change0
Corewell Health40100%100%100%no change0
Zing Health Consolidator, Inc36100%100%100%no change0
CAPITAL BLUE CROSS35100%100%100%no change0
Medica Holding Company31100%100%100%no change0
UPMC Health System30100%100%100%no change19
Universal Health Services, Inc.29100%100%100%no change0
MHH Healthcare, L.P.26100%100%100%no change0
Independence Health Group, Inc.25100%100%100%no change0
Point32Health, Inc.23100%100%100%+100 points19
BlueCross BlueShield of Tennessee22100%100%100%no change0
California Physicians' Service22100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Linzess?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing